Condition: BCR-JAK2 Fusion Protein Expression · Blasts 20 Percent or Less of Peripheral Blood White Cells · Blasts More Than 5 Percent of Bone Marrow Nucleated Cells · Sponsor: William Shomali
This phase II trial studies how well ruxolitinib works in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders.
This description comes directly from the study's public registry record.
Tiffany Nguyen · 650-725-9167 · tnguye10@stanford.edu
Always discuss trial participation with your own doctor first.
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | Recruiting |
| OHSU Knight Cancer Institute | Portland, Oregon, United States | Terminated |
| University of Utah | Salt Lake City, Utah, United States | Terminated |
| Fred Hutchinson cancer research center | Seattle, Washington, United States | Terminated |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03801434